Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Authors:
- Meiling ChenMCMeiling Chen
- Yuanzhong ChenYCYuanzhong Chen
- Shaoyuan WangSWShaoyuan Wang
- Feng’E YangFYFeng’E Yang
- Jing ZhengJZJing Zheng
- Danhui FuDFDanhui Fu
- Jia LinJLJia Lin
- Xiaofan LiXLXiaofan Li
- Nainong LiNLNainong Li
- 29 July 2026
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , e1218-e1228.e3
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory FLT3 ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 PatientsAmerican Journal of Hematology, 2025
- Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemiaLeukemia, 2024
- Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemiaLeukemia Research, 2024
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AMLBlood Cancer Journal, 2022
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemiaBlood Cancer Journal, 2021
- The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemiaCancer Medicine, 2020
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialThe Lancet Oncology, 2020
- Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemiaAmerican Journal of Hematology, 2020
- Targeting FLT3 mutations in AML: review of current knowledge and evidenceLeukemia, 2019